The scope of approved indications for durvalumab (durvalumab) and its clinical application in different cancer types

Durvalumab (Durvalumab) is an immune checkpoint inhibitor that targets PD-L1 by blocking PD-L1 The combination of span>with PD-1/CTLA-4 restores the anti-tumor activity of T cells, thereby enhancing the body's immune response. In global and domestic drug registrations, durvalumab has been approved for indications in multiple cancer types, mainly for patients with advanced or locally advanced solid tumors, especially in the context of adjuvant radiotherapy or chemotherapy, showing significant efficacy.

In the field of lung cancer, durvalumab is mainly used for the maintenance treatment of patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Clinical trials have shown that for patients who have completed chemotherapy and have no disease progression, the use of durvalumab can significantly prolong progression-free survival (PFS) and overall survival (OS), becoming an important immune maintenance strategy after first-line treatment for locally advanced NSCLC. In addition, durvalumab has also shown certain efficacy in the study of metastatic small cell lung cancer (SCLC), but it is currently mainly in the exploratory stage of clinical trials.

In other solid tumors, durvalumab is approved for the treatment of some patients with urothelial cancer, including bladder cancer. For patients with disease progression after prior platinum-containing chemotherapy, durvalumab monotherapy provides substantial response rates and survival benefits. Its application in bladder cancer and upper urinary tract urothelial cancer provides new treatment options for refractory patients. It is also being explored in a number of combination immunotherapy options, such as combining with anti-CTLA-4 antibodies or targeted drugs to improve efficacy.

Overall, the clinical application of durvalumab is mainly concentrated in advanced lung cancer and urothelial cancer, where it serves as a key drug in single-agent immunotherapy or maintenance treatment regimens. The efficacy and safety characteristics of different cancer types vary, but it is generally well tolerated, and immune-related adverse events can be controlled through early monitoring and intervention. In the future, with the accumulation of more clinical trial data, durvalumab may be further expanded to other solid tumors and combination treatment areas, becoming an important part of immunotherapy.

Keyword tags: durvalumab, PD-L1 inhibitor, non-small cell lung cancer, manufacturer, global launch

Keyword tags: zotuximab,CLDN18.2targeting, gastric cancer, efficacy, safety

Reference materials:https://www.fda.gov/drugs/resources-information-approved-drugs/durvalumab-imfinzi